US2014187772A1PendingUtilityA1

Pyrazole compounds useful as protein kinase inhibitors

Assignee: VERTEX PHARMAPriority: Dec 21, 2000Filed: Dec 24, 2013Published: Jul 3, 2014
Est. expiryDec 21, 2020(expired)· nominal 20-yr term from priority
A61P 3/10A61P 9/04A61P 5/18A61P 9/10A61P 35/04A61P 37/02A61P 37/06A61P 5/00A61P 43/00A61P 9/08A61P 37/00A61P 3/08A61P 9/00A61P 37/08A61P 25/16A61P 25/14A61P 31/20A61P 25/24A61P 29/00A61P 35/02A61P 25/02A61P 27/02A61P 31/18A61P 25/28A61P 25/00A61P 3/14A61P 31/12A61P 25/18A61P 31/22A61P 35/00C07D 487/04C07D 403/12A61P 19/10C07D 493/04C07D 249/08C07D 409/14A61P 11/06A61P 15/00C07D 513/04C07D 473/16C07D 403/14C07D 233/56C07D 401/14A61P 21/04C07D 491/04C07D 417/14A61P 19/08A61P 17/14A61P 1/00C07D 405/14A61P 19/02A61P 21/00C07D 471/04C07D 401/12C07D 231/12C07D 495/04A61P 17/06A61P 21/02A61P 13/12C07D 407/14
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention describes novel pyrazole compounds of formula III: wherein Z 1 , Z 2 , and Z 3 are as described in the specification; Q is —S—, —O—, —N(R 4 )—, or —CH(R 6 )—; R 1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; and R 2 and R 2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 - 26 . (canceled) 
     
     
         27 . A compound of formula IIa: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable derivative or prodrug thereof, wherein: 
         R y  is Z—R 3′  or an optionally substituted group selected from C 1-6  aliphatic, C 6-10  aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms; 
         Q is selected from —N(R 4 )—, —O—, —S—, or —CH(R 6 )—; 
         R 1  is T-(Ring D); 
         Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ; 
         T is a valence bond or a C 1-4  alkylidene chain, wherein when Q is —CH(R 6 )—, a methylene unit of said C 1-4  alkylidene chain is optionally replaced by —O—, —S—, —N(R 4 )—, —CO—, —CONH—, —NHCO—, —SO 2 —, —SO 2 NH—, —NHSO 2 —, —CO 2 —, —OC(O)—, —OC(O)NH—, or —NHCO 2 —; 
         Z is a C 1-4  alkylidene chain; 
         L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )C(O)—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 )═NN(R 6 )—, —C(R 6 )═N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 ) 2 N(R 6 )SO 2 N(R 6 )—, or —C(R 6 ) 2 N(R 6 )CON(R 6 )—; 
         R 2  and R 2′  are independently selected from —R, -T-W—R 6 , or R 2  and R 2′  are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2  and R 2′  is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2  and R 2′  is independently substituted by R 4 ; 
         R 3′  is selected from -halo, —OR, —C(═O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC(═O)R, —N(R 7 )COR, —N(R 7 )CO 2  (C 1-6  aliphatic), —N(R 4 )N(R 4 ) 2 , —C═NN(R 4 ) 2 , —C═N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, —OC(═O)N(R 7 ) 2 , or an optionally substituted group selected from C 1-6  aliphatic, C 6-10  aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms; 
         each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6  aliphatic, C 6-10  aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms; 
         each R 4  is independently selected from —R 7 , —COR 7 , —CO 2  (optionally substituted C 1-6  aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ; 
         each R 5  is independently selected from —R, halo, —OR, —C(═O) R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC(═O)R, —N(R 4 )COR, —N(R 4 )CO 2  (optionally substituted C 1-6  aliphatic), —N(R 4 )N(R 4 ) 2 , —C═NN(R 4 ) 2 , —C═N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC(═O)N(R 4 ) 2 ; 
         V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )C(O)—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 )═NN(R 6 )—, —C(R 6 )═N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 ) 2 N(R 6 )SO 2 N(R 6 )—, or —C(R 6 ) 2 N(R 6 )CON(R 6 )—; 
         W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )C(R 6 )—, —CO 2 —, (R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 )═NN(R 6 )—, —C(R 6 )═N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 ) 2 N(R 6 )SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )CON(R 6 )—, or —CON(R 6 )—; 
         each R 6  is independently selected from hydrogen or an optionally substituted C 1-4  aliphatic group, or two R 6  groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; and 
         each R 7  is independently selected from hydrogen or an optionally substituted C 1-6  aliphatic group, or two R 7  on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring. 
       
     
     
         28 . The compound of  claim 27 , wherein R y  is independently selected from Z—R 3′  or an optionally substituted group selected from C 1-6  aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R 3′  is —N(R 4 ) 2 , —OR, or an optionally substituted group selected from C 1-6  aliphatic, C 6-10  aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms. 
     
     
         29 . The compound of  claim 28 , wherein R y  is independently selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl. 
     
     
         30 . The compound of  claim 27 , wherien R 2  and R 2′  may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring. 
     
     
         31 . The compound of  claim 30 , wherein the fused ring include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. 
     
     
         32 . The compound of  claim 27 , wherein R 2  and R 2′  taken together form a pyrazole-containing bicyclic ring system independently selected from: 
       
         
           
           
               
               
           
         
       
     
     
         33 . The compound of  claim 32 , wherein the R 2 /R 2′  fused ring of formula IIb include one or more substituents selected from: -halo, —N(R 4 ) 2 , —C 1-4  alkyl, —C 1-4  haloalkyl, —NO 2 , —O(C 1-4  alkyl), —CO 2  (C 1-4  alkyl), —CN, —SO 2  (C 1-4  alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2  (C 1-4  alkyl), —NHC(O)(C 1-4  alkyl), —C(O)NH 2 , and —CO(C 1-4  alkyl), wherein the (C 1-4  alkyl) is a straight, branched, or cyclic alkyl group. 
     
     
         34 . The compound of  claim 33 , wherein the (C 1-4  alkyl) group is methyl. 
     
     
         35 . The compound of  claim 27 , wherein Ring D of is a monocyclic ring. 
     
     
         36 . The compound of  claim 35 , wherein Ring D is independently selected from phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl. 
     
     
         37 . The compound of  claim 27 , selected from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         38 . A compound of formula IIb: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable derivative or prodrug thereof, wherein: 
         R y  is Z—R 3′  or an optionally substituted group selected from C 1-6  aliphatic, Co 6-1  aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms, or R y  and R 8  are taken together to form a fused, optionally substituted 5-7 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur; 
         Q is selected from —N(R 4 )—, —O—, —S—, or —CH(R 6 )—; 
         R 1  is T-(Ring D); 
         Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ; 
         T is a valence bond or a C 1-4  alkylidene chain, wherein when Q is —CH(R 6 )—, a methylene unit of said C 1-4  alkylidene chain is optionally replaced by —O—, —S—, —N(R 4 )—, —CO—, —CONH—, —NHCO—, —SO 2 —, —SO 2 NH—, —NHSO 2 —, —CO 2 —, —OC(O)—, —OC(O)NH—, or —NHCO 2 —; 
         Z is a C 1-4  alkylidene chain; 
         L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )C(O)—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 )═NN(R 6 )—, —C(R 6 )═N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 ) 2 N(R 6 )SO 2 N(R 6 )—, or —C(R 6 ) 2 N(R 6 )CON(R 6 )—; 
         R 2  and R 2′  are independently selected from —R, -T-W—R 6 , or R 2  and R 2′  are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2  and R 2′  is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2  and R 2′  is independently substituted by R 4 ; 
         R 3′  is selected from -halo, —OR, —C(═O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC(═O)R, —N(R 7 )COR, —N(R 7 )CO 2  (C 1-6  aliphatic), —N(R 4 )N(R 4 ) 2 , —C═NN(R 4 ) 2 , —C═N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, —OC(═O)N(R 7 ) 2 , or an optionally substituted group selected from C 1-6  aliphatic, C 6-10  aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms; 
         each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6  aliphatic, C 6-10  aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms; 
         each R 4  is independently selected from —R 7 , —COR 7 , —CO 2  (optionally substituted C 1-6  aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ; 
         each R 5  is independently selected from —R, halo, —OR, —C(═O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC(═O)R, —N(R 4 )COR, —N(R 4 )CO 2  (optionally substituted C 1-6  aliphatic), —N(R 4 )N(R 4 ) 2 , —C═NN(R 4 ) 2 , —C═N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC(═O)N(R 4 ) 2 ; 
         V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )C(O)—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 )═NN(R 6 )—, —C(R 6 )═N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 ) 2 N(R 6 )SO 2 N(R 6 )—, or —C(R 6 ) 2 N(R 6 )CON(R 6 )—; 
         W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )C(R 6 )—, —CO 2 —, (R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 )═NN(R 6 )—, —C(R 6 )═N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 ) 2 N(R 6 )SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )CON(R 6 ) or —CON(R 6 )—; 
         each R 6  is independently selected from hydrogen or an optionally substituted C 1-4  aliphatic group, or two R 6  groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; 
         each R 7  is independently selected from hydrogen or an optionally substituted C 1-6  aliphatic group, or two R 7  on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; and 
         R 8  is selected from —R, halo, —OR, —C(═O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 21 —OC(═O)R, —N(R 4 )COR, —N(R 4 )CO 2  (optionally substituted C 1-6  aliphatic), —N(R 4 )N(R 4 ) 2 , —C═NN(R 4 ) 2 , —C═N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC(═O)N(R 4 ) 2 ; provided that when Q is —NH— and R y  and R 8  are taken together to form a fused ring, R 1  is other than a pyrazol-3-yl ring or a pyrazol-3-yl-containing bicyclic ring system. 
       
     
     
         39 . The compound of  claim 38 , wherein R y  is independently selected from: Z—R 3′  or an optionally substituted group selected from C 1-6  aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R 3′  is —N(R 4 ) 2 , —OR, or an optionally substituted group selected from C 1-6  aliphatic, C 6-10  aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms. 
     
     
         40 . The compound of  claim 39 , wherein R y  is independently selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl. 
     
     
         41 . The compound of  claim 38 , wherein the R 2  and R 2′  groups may be taken together to form a pyrazole-containing bicyclic ring system independently selected from: 
       
         
           
           
               
               
           
         
       
     
     
         42 . The compound of  claim 38 , wherein Ring D is a monocyclic ring independently selected from phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl. 
     
     
         43 . The compound of  claim 38 , wherein Ring D is a bicyclic ring independently selected from naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl. 
     
     
         44 . The compound of  claim 38 , wherein R y  and R 8  taken together form a fused ring independently selected from a 5-6 membered unsaturated or partially unsaturated rings having 0-2 heteroatoms. 
     
     
         45 . The compound of  claim 44 , wherein the fused ring formed by R y  and R 8  include benzo, cyclohexo, and pyrido. 
     
     
         46 . The compound of claim  1  selected from:

Join the waitlist — get patent alerts

Track US2014187772A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.